Munich-based digital health startup XO Life has closed a new €4 million funding round. The round was led by Fil Rouge Capital, with participation from existing investors Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital. The company plans to use the capital to further scale its AI-powered patient-pharmaceutical platform "Brite," automate pharmaceutical onboarding, and accelerate its expansion in Europe.
What's remarkable about XO Life is less the sheer size of the funding than the positioning of the platform: Unlike fragmented, standalone solutions, the startup offers a unified meta-platform...which works across all medications, therapies, and indications. This approach is particularly relevant in the European digital health market because pharmaceutical and medtech companies increasingly want to standardize their patient communication, ensure regulatory compliance, and roll it out across multiple markets.
Fil Rouge Capital is leading the financing round
The current funding round is led by Fil Rouge Capital, an investor focused on early-stage financing from pre-seed to Series A. The fact that several existing investors are also participating again is an important signal for XO Life: the cap table not only remains international, but also demonstrates support for the move into the next growth phase towards Series A.
This is interesting for the market because follow-on investments in digital health have become significantly more selective than a few years ago. When existing investors inject further capital in such an environment, it usually indicates strong revenue signals, product-market fit, or clear sales prospects in the B2B sector.
"This funding is a testament to the strong demand for a unified, high-quality patient-pharmaceutical platform,"
said Dr. Friderike Bruchmann, CEO of XO Life, and continues:
“We already work with more than 40 pharmaceutical companies, including three of the ten largest global players. This investment will allow us to accelerate the development of our ‘Brite’ platform, leverage AI across all functions, and automate pharmaceutical onboarding across entire portfolios.”
“Brite” as infrastructure for digital therapy support
At the heart of the business model is the "Brite" platform, which XO Life positioned in early 2025 as a further development and consolidation of previous product components. The company describes it as a global meta-platform for digital product and therapy support, enabling pharmaceutical and medtech providers to offer patient-related information, support, and monitoring within a shared infrastructure.
The decisive advantage is scalability: XO Life Instead of developing a separate app for each medication, they are developing a central platform that can be used for many therapies and markets simultaneously.
For pharmaceutical companies, this means they can roll out digital offerings faster and more easily. For patients, the advantage is that they don't have to use multiple different applications. Therefore, XO Life is primarily investing the new capital in AI features and processes that make it easier for pharmaceutical companies to quickly get on board the platform.
Following the €7 million in 2024, the next growth financing will follow.
This current funding round is not the company's first major capital raising. XO Life already held a funding round in August 2024. Financing exceeding 7 million euros received funding. At the time, investors included Sandwater, Grazia Equity, Vi Partners, and Bayern Kapital. The startup had already raised more than €2 million by 2022.
This reveals a consistent trajectory: first the development of the platform, then internationalization, and now the next funding stage to scale the model in Europe. This is particularly relevant for a Munich-based healthtech company, XO Life, because it doesn't rely on a classic D2C model, but rather operates at the interface between patients, medical professionals, and the pharmaceutical industry. This brings together factors such as long sales cycles and high demands on trust, medical quality, and feasibility.
What this round means for Munich as a digital health location
For Munich, this funding round is a further indication that even in the increasingly challenging financing environment, B2B-oriented digital health models with clear industrial ties can secure capital. XO Life is not only drawing attention to patient experience, but also to an infrastructure problem in the healthcare market. Individual solutions for each product cannot be the answer. Instead, what is needed is the digital scaling of validated information, interactions, and therapy support.
